Shares in TigerMed Consulting, the region’s largest healthcare deal of the year so far, rocketed on their debut in Hong Kong on Friday. The secondary listing of the China-based provider of comprehensive biopharmaceutical R&D services closed up 13.3%. The company, which is the country’s largest clinical CRO and already listed in Shenzhen, raised HK$10.7bn (US$1.4bn)…
©2023 All rights reserved LaingBuisson 
